American Century Companies Inc. lifted its stake in Insulet Co. (NASDAQ:PODD) by 12.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 786,334 shares of the medical instruments supplier’s stock after acquiring an additional 85,442 shares during the period. American Century Companies Inc. owned approximately 1.33% of Insulet worth $62,372,000 at the end of the most recent reporting period.
Several other institutional investors also recently made changes to their positions in PODD. Vanguard Group Inc. raised its holdings in shares of Insulet by 1.7% in the third quarter. Vanguard Group Inc. now owns 5,053,657 shares of the medical instruments supplier’s stock valued at $535,434,000 after buying an additional 84,209 shares during the last quarter. Vanguard Group Inc raised its holdings in shares of Insulet by 1.7% in the third quarter. Vanguard Group Inc now owns 5,053,657 shares of the medical instruments supplier’s stock valued at $535,434,000 after buying an additional 84,209 shares during the last quarter. Clearbridge Investments LLC raised its holdings in shares of Insulet by 5.6% in the third quarter. Clearbridge Investments LLC now owns 1,823,750 shares of the medical instruments supplier’s stock valued at $193,226,000 after buying an additional 96,266 shares during the last quarter. Norges Bank bought a new position in shares of Insulet in the fourth quarter valued at about $53,604,000. Finally, First Trust Advisors LP raised its holdings in shares of Insulet by 103.6% in the fourth quarter. First Trust Advisors LP now owns 458,028 shares of the medical instruments supplier’s stock valued at $36,331,000 after buying an additional 233,075 shares during the last quarter.
PODD has been the subject of a number of research analyst reports. Morgan Stanley cut their price target on Insulet from $105.00 to $90.00 and set an “equal weight” rating for the company in a report on Wednesday, January 2nd. BidaskClub cut Insulet from a “buy” rating to a “hold” rating in a report on Thursday, April 11th. Canaccord Genuity lifted their price target on Insulet from $90.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, February 19th. Northland Securities reaffirmed a “buy” rating and issued a $100.00 price target on shares of Insulet in a report on Tuesday, February 26th. Finally, ValuEngine cut Insulet from a “strong-buy” rating to a “buy” rating in a report on Monday, January 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $103.20.
Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Monday, February 25th. The medical instruments supplier reported $0.16 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.10. Insulet had a return on equity of 1.73% and a net margin of 0.58%. The business had revenue of $164.90 million during the quarter, compared to analyst estimates of $162.45 million. During the same period in the previous year, the firm earned ($0.12) EPS. Insulet’s quarterly revenue was up 26.4% compared to the same quarter last year. Equities research analysts predict that Insulet Co. will post 0.23 EPS for the current fiscal year.
In other Insulet news, EVP Aiman Abdel-Malek sold 1,608 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $95.22, for a total value of $153,113.76. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Michael L. Levitz sold 1,350 shares of the business’s stock in a transaction that occurred on Wednesday, February 27th. The shares were sold at an average price of $92.01, for a total value of $124,213.50. The disclosure for this sale can be found here. Insiders sold a total of 91,964 shares of company stock valued at $8,526,720 over the last quarter. 3.50% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This article was posted by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/04/26/american-century-companies-inc-increases-holdings-in-insulet-co-podd.html.
Insulet Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.